Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Advancing pharmacovigilance in a changing landscape: 2024 World Drug Safety Congress
With over 1,500 registered attendees, the 2024 World Drug Safety Congress brought together pharmacovigilance experts to discuss the challenges and solutions in their profession. ICON experts who were there reflect on the topics discussed and look at the emerging trends.
-
Celebrating World Children’s Day
To mark World Children's Day we reflect on ICON’s commitment to increase pediatric healthcare access and inclusion by supporting pediatric clinical trials.
-
Preparing for EMA policy 0070
Clinical trial data must be anonymised to protect patient privacy and business information, yet transparent enough to be useful for other researchers.
-
Data Transparency: Variances in patient and claims counts explained
This blog explains how Symphony Health’s commitment to data transparency ensures clients can confidently interpret and utilise their refreshed datasets.
-
Investigating multi-indication drug targets
This blog will explore some of the multi-indication drug targets that have already been developed in multiple applications, as well as considerations for entering clinical trials, such as building evidence and trial design.
-
Navigating early phase challenges for biotechs
To better understand the concerns of biotechs in early phases, ICON conducted a survey of 149 professionals representing small- and medium-sized biotech organisations from North America and Europe.
-
The importance of communication in patient-centred clinical trials
How can we navigate this complex linguistic landscape while preserving the integrity of the original message and keep participants well informed?
-
Obesity-related liver conditions: Understanding treatment options
Explore obesity’s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
-
Designing clinical trials for a complex disease: Pediatric obesity
Pediatric obesity is a complex disease with multiple factors for sponsors to consider when designing and executing treatment trials.
-
The importance of a robust clinical outcome assessment strategy in your clinical trial
At ICON, we understand the nuances involved in creating a COA strategy that not only meets regulatory standards but also resonates with patients and stakeholders alike.
-
How an eCOA library can reduce your study start up timelines
Learn about the benefits of developing an eCOA library and how a strong eCOA strategy can help reduce screenshot review step by five weeks.
-
A dynamic market: Trends transforming the future of obesity drug development
Learn about the future of obesity drug development and explore how GLP-1 drugs and multi-indication therapies are transforming treatment.
-
Submission strategies for combined studies in the EU
In this article we look at how an oncology study sponsor managed their submission process which spanned more than 30 countries, many in the EU.
-
Maximising clinical trial success with integrated language services
Translation management is a critical component in global clinical trials - accurate and culturally appropriate communication is non-negotiable. Learn the importance of integrated language services in clinical research.
-
The benefits of going big: Why small biotechs need large CRO partners
Small biotech companies can gain significant benefits by partnering with a big CRO – if it’s the right fit. We outline some of the benefits of strategic partnerships for cash-constrained biotech.
-
Accelerating ATMP and CGT: The importance of Regulatory CMC expertise in efficient biologics development
Discover how dedicated Regulatory CMC expertise benefits biologics development, ensuring compliance and efficiency, especially for innovative therapies like ATMPs and CGTs.
-
Why using COAs and DHTs together is the future of clinical research
Though both COAs and DHTs are tools used to evaluate a treatment’s impact, they often exist in separate spheres, rarely integrated. We argue that combining these two approaches in the same study can help researchers gather better data and improve the likelihood of regulatory approval.
-
Enhancing diversity in clinical trials
To fully assess the efficacy and safety of a therapeutic indication, clinical trials must evaluate populations that are representative of the treatment population, as different people may experience the same disease differently.
-
Unlocking the value of transparent healthcare data
In this blog, we'll explore how transparency in healthcare data can unlock its full potential. Discover why transparency matters and how Symphony Health’s approach ensures you get the most accurate, actionable insights.
-
Digital health: Why evaluating human factors is essential
With the rapidly evolving technology, digital health is transforming healthcare, emerging as a promising solution to reduce rising healthcare costs and improve patient care.